AFF4 Activators
Chemicals classified as AFF4 activators primarily function by indirectly influencing AFF4 activity within the super elongation complex (SEC). AFF4, being a part of SEC, plays a crucial role in transcription elongation, and its activity is tightly intertwined with the overall dynamics of the complex. The chemicals listed above predominantly target proteins and processes that are closely associated with transcription regulation, such as bromodomain-containing proteins, cyclin-dependent kinases (CDKs), and histone acetyltransferases.
For instance, inhibitors of BET bromodomains, like JQ1, I-BET151, and OTX015, disrupt the function of BRD4, a key component of the SEC. By modulating BRD4 activity, these compounds indirectly affect the composition and functionality of the SEC, thereby potentially influencing AFF4 activity. Similarly, CDK inhibitors like Flavopiridol and Dinaciclib target CDKs involved in transcription regulation. By inhibiting CDK9, these compounds can alter the phosphorylation status of RNA polymerase II, thereby impacting transcription elongation processes where AFF4 plays a significant role. Additionally, compounds targeting histone acetyltransferases (p300/CBP) and histone deacetylases (HDACs),
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BML-278 | 15301-69-6 | sc-396999 sc-396999A | 5 mg 25 mg | $84.00 $335.00 | ||
I-BET151 is another BET bromodomain inhibitor that could impact AFF4 activity indirectly by modifying SEC dynamics through BRD4 inhibition. | ||||||
(S)-2-(4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide | 202590-98-5 | sc-501130 | 2.5 mg | $330.00 | ||
OTX015, targeting BET bromodomains, particularly BRD4, may affect AFF4 function within the SEC by altering transcriptional regulation. | ||||||
Flavopiridol Hydrochloride | 131740-09-5 | sc-207687 | 10 mg | $317.00 | ||
Flavopiridol, a CDK9 inhibitor, might indirectly activate AFF4 by influencing the phosphorylation status of the RNA polymerase II C-terminal domain, affecting transcription elongation. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib, another CDK inhibitor, may indirectly impact AFF4 by modulating the activity of CDKs involved in transcription regulation, such as CDK9. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032, a CDK inhibitor with specificity for CDK2, 7, and 9, might alter AFF4 activity indirectly through its effects on transcription elongation processes. | ||||||
A-485 | 1889279-16-6 | sc-507493 | 5 mg | $275.00 | ||
A-485, a potent and selective catalytic inhibitor of p300/CBP, could influence AFF4 activity indirectly by affecting histone acetylation and transcriptional regulation. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
MS-275, a HDAC inhibitor, might indirectly activate AFF4 by changing the chromatin state and thereby affecting transcription elongation processes in which AFF4 is involved. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat, another HDAC inhibitor, could indirectly affect AFF4 activity through alterations in chromatin structure and transcriptional regulation. | ||||||